Pharma News
FDA Issues Complete Response Letter to Supernus for SPN-830, a Potential Treatment for Motor Fluctuations in Parkinson Disease
![](https://meefro.com/wp-content/uploads/2024/04/FDA-Issues-Complete-Response-Letter-to-Supernus-for-SPN-830-a-780x470.png)
According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.
Source link
#FDA #Issues #Complete #Response #Letter #Supernus #SPN830 #Potential #Treatment #Motor #Fluctuations #Parkinson #Disease